News Oncopeptides AB

Equities

ONCO

SE0009414576

Market Closed - Nasdaq Stockholm Other stock markets 11:29:42 2024-04-18 am EDT			5-day change	1st Jan Change
4.54 ^SEK	+1.57%		-9.74%	-40.73%

Apr. 04	Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	CI
Mar. 27	Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncopeptides publishes prospectus relating to the rights issue	Apr. 17	AQ
Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)	Apr. 15	AQ
Oncopeptides secures national reimbursement for Pepaxti in Spain	Apr. 15	AQ
Oncopeptides announces final terms for the fully guaranteed rights issue	Apr. 08	AQ
Oncopeptides releases first quarter 2024 sales	Apr. 04	AQ
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	Apr. 04	CI
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	CI
Extraordinary General Meeting in Oncopeptides AB (publ)	Mar. 13	AQ
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	Mar. 13	MT
Oncopeptides : Oncopeptalks on the company's rights issue	Mar. 13	PU
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026	Mar. 13	AQ
FDA Flexes Its New FDORA Muscles In Withdrawing An Accelerated Approval	Mar. 08	AQ
Oncopeptides PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	Mar. 04	AQ
Oncopeptides : to present at two investor events	Mar. 04	PU
Oncopeptides AB - Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	Mar. 01	AQ
Oncopeptides' : PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	Mar. 01	PU
Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	Mar. 01	AQ
Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	Feb. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oncopeptides AB

Equities

ONCO

SE0009414576

Summary

Filters